Asset
MITOMYCIN
UroGen Pharma Ltd. Ordinary Shares
Revenue
No revenue reported in loaded filings.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03558503 | phase2 | completed | 2018-10-15 | 2020-01-03 | UroGen Pharma Ltd. | A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer |
| NCT05243550 | phase3 | active_not_recruiting | 2022-03-01 | 2023-04-26 | UroGen Pharma Ltd. | A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer |
| NCT04688931 | phase3 | terminated | 2021-02-19 | 2023-03-17 | UroGen Pharma Ltd. | A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer |
| NCT05136898 | phase3 | completed | 2021-11-30 | 2023-02-02 | UroGen Pharma Ltd. | Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC) |
FDA applications (2)
| Application | Type | Applicant |
|---|---|---|
| NDA 211728 | NDA | UROGEN PHARMA LTD |
| NDA 215793 | NDA | UROGEN PHARMA LTD |
Marketed products (2)
- JELMYTO
- ZUSDURI